

**Regd. Office :**

'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com

July 30, 2014

Bombay stock Exchange Limited  
1<sup>st</sup> Floor, P.J. Towers  
Dalal Street  
MUMBAI – 400 001

**Kind Attn.:** Mr. Kapoor  
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G Block  
Bandra-Kurla Complex  
Bandra – (East)  
Mumbai – 400 051

**Kind Attn.:** Famroze Pochara  
Asst. Vice President

Ahmedabad Stock Exchange Limited  
Kamdhenu Complex  
Opp. Sahajanand College  
Panjara Pole,  
Ahmedabad – 380 015


Dear Sirs

**Re.:** Unaudited financial results for the quarter ended on June 30, 2014.

We are forwarding herewith unaudited financial results for the quarter ended on June 30, 2014 reviewed by Audit Committee and taken on record by the Board of Directors on July 30, 2014 pursuant to Clause 41 of the Listing Agreement; the same may please receive in order.

Thanking you

Yours faithfully  
For **CADILA HEALTHCARE LIMITED**

  
**UPEN H. SHAH**  
**COMPANY SECRETARY**

**Encl.:** As above

**PART I**

**Statement of Results for the Quarter Ended 30/06/2014**

CONSOLIDATED				COMPANY			
Rupees in Lacs		Rupees in Lacs		Rupees in Lacs		Rupees in Lacs	
3 Months ended 30/06/2014 (Unaudited)	Preceding 3 months ended 31/03/2014 (Audited)	3 months ended 30/06/2013 in the previous year (Unaudited)	Previous year ended 31/03/2014 (Audited)	3 Months ended 30/06/2014 (Unaudited)	Preceding 3 months ended 31/03/2014 (Audited)	3 months ended 30/06/2013 in the previous year (Unaudited)	Previous year ended 31/03/2014 (Audited)
St. No.	Particulars	St. No.	Particulars	St. No.	Particulars	St. No.	Particulars
1	Income from operations	1	Gross Sales	100,372	100,478	81,234	358,733
	Less: Excise Duty		1,681	1,681	1,436	1,532	6,280
a	Net Sales		98,691	98,691	99,042	79,702	352,453
b	Other operating income		12,588	12,588	11,112	13,108	51,758
c	Total income from operations (net)		111,279	111,279	110,154	92,810	404,211
2	Expenses						
a	Cost of materials consumed		31,655	31,655	26,673	24,864	106,814
b	Purchases of stock-in-trade		11,837	11,837	10,580	8,920	38,266
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade		15,176	15,176	32	(2,422)	(3,571)
d	Employee benefits expense		5,295	5,295	13,303	13,409	52,514
e	Depreciation and amortisation expense		31,715	31,715	3,217	3,039	12,740
f	Other expenses		90,189	90,189	32,079	30,473	129,489
g	Total expenses		21,090	21,090	85,884	78,283	336,252
3	Profit/(Loss) from Operations before other income, finance costs and exceptional items (1-2)		1,634	1,634	24,270	14,527	67,959
4	Other income		22,724	22,724	2,035	21,954	30,859
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)		825	825	26,305	36,481	98,818
6	Finance costs		21,899	21,899	1,001	1,460	4,251
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)		0	0	25,304	35,021	94,567
8	Exceptional items		21,899	21,899	0	0	0
9	Profit/(Loss) from ordinary activities before tax (7-8)		21,899	21,899	25,304	35,021	94,567
10	Tax expense		2,170	2,170	3,636	999	4,288
11	Net Profit/(Loss) from ordinary activities after tax (9-10)		19,729	19,729	21,668	34,022	90,359
12	Extraordinary items (net of tax expense)		0	0	0	0	0
13	Net Profit/(Loss) for the period (11-12)		19,729	19,729	21,668	34,022	90,359
14	Share of profit/(loss) of associates		0	0	0	0	0
15	Minority interest		(691)	(691)	(723)	(799)	(833)
16	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13+14+15)		24,021	24,021	20,305	33,223	89,526
17	Paid-up equity share capital (Face Value Rs. 5/-)		19,729	19,729	21,668	34,022	90,359
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year		10,237	10,237	10,237	10,237	10,237
19	Earnings per share (before extraordinary items) (of Rs. 5/- each)		10,237	10,237	10,237	10,237	352,754
a	Basic (Rs.)		11,73	11,68	9,53	9,53	44,13
b	Diluted (Rs.)		11,73	11,68	9,53	9,53	44,13
19	Earnings per share (after extraordinary items) (of Rs. 5/- each) (not annualised):		11,73	11,68	9,53	9,53	44,13
a	Basic (Rs.)		11,73	11,68	9,53	9,53	44,13
b	Diluted (Rs.)		11,73	11,68	9,53	9,53	44,13

(1) The above results for the quarter ended on June 30, 2014 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on July 30, 2014.

(2) The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per clause 41 of the Listing Agreement.

(3) Effective from April 1, 2014, the Company has changed the depreciation charge based on the revised remaining useful lives of the assets as per the requirement of Schedule II of the Companies Act, 2013. Due to this, the depreciation charge for the quarter ended June 30, 2014 is higher by Rs. 1,613 Lacs on Standalone basis [Rs. 1,838 Lacs on Consolidated basis]. Further, based on transitional provision provided in Note 7(i) of Schedule II, an amount of Rs. 2,497 Lacs on Standalone basis [Rs.2,594 Lacs on Consolidated basis], which pertains to the carrying value of the assets whose remaining useful life as on April 1, 2014 is "Nil", has been adjusted to the Retained Earnings.

(4) The Company has incorporated Zydus Discovery DMCC as a wholly owned subsidiary in Dubai on June 15, 2014.

(5) The changes in investments during the quarter are as under:  
Zydus Worldwide DMCC (Indial Investments) - Rs. 8 Lacs  
Zydus Healthcare Philippines Inc. (Additional Investments) - Rs. 8 Lacs

(6) Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.


(7) The Company has one segment of activity viz., "Pharmaceuticals".

## PART II

## Select Information for the Quarter Ended 30/06/2014

3 Months ended 30/06/2014	Preceding 3 months ended 31/03/2014	Corresponding 3 months ended 30/06/2013 in the previous year	Previous year ended 31/03/2014	Particulars	3 Months ended 30/06/2014	Preceding 3 months ended 31/03/2014	Corresponding 3 months ended 30/06/2013 in the previous year	Previous year ended 31/03/2014
51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	<b>PARTICULARS OF SHAREHOLDING</b> <b>Public shareholding</b> - Number of shares - Percentage of Shareholding <b>Promoters and Promoter Group Shareholding</b> <sup>a</sup> Pledged / Encumbered <sup>b</sup> Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) Non - encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of Promoter and Promoter group) - Percentage of shares (as a % of the total share capital of the company)	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%
Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.		Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.
153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	<b>INVESTOR COMPLAINTS [In Numbers]</b> Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%
Nil N/A	Nil N/A	Nil N/A	Nil N/A		Nil N/A	Nil N/A	Nil N/A	Nil N/A
				Particulars	3 months ended 30/06/2014			
					Nil			
					7			
					6			
					1			

Ahmedabad, July 30, 2014

By Order of the Board,  
 For Cadila Healthcare Limited,  
  
 Pankaj R. Patel  
 Chairman & Managing Director